172 related articles for article (PubMed ID: 15625372)
21. Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.
Hasan B; Greillier L; Pallis A; Menis J; Gaafar R; Sylvester R; Fennell DA; Baas P; Surmont V; Van Meerbeeck JP; O'brien ME
Eur J Cancer; 2014 Nov; 50(16):2771-82. PubMed ID: 25155251
[TBL] [Abstract][Full Text] [Related]
22. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
[TBL] [Abstract][Full Text] [Related]
23. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.
Van Schil PE; Baas P; Gaafar R; Maat AP; Van de Pol M; Hasan B; Klomp HM; Abdelrahman AM; Welch J; van Meerbeeck JP;
Eur Respir J; 2010 Dec; 36(6):1362-9. PubMed ID: 20525721
[TBL] [Abstract][Full Text] [Related]
24. Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma.
Maruyama R; Shoji F; Okamoto T; Miyamoto T; Miyake T; Nakamura T; Ikeda J; Aoki Y; Wataya H; Asoh H; Ichinose Y
Jpn J Clin Oncol; 2005 Aug; 35(8):433-8. PubMed ID: 16006571
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
Tomek S; Manegold C
Lung Cancer; 2004 Aug; 45 Suppl 1():S103-19. PubMed ID: 15261443
[TBL] [Abstract][Full Text] [Related]
26. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
Bottomley A; Gaafar R; Manegold C; Burgers S; Coens C; Legrand C; Vincent M; Giaccone G; Van Meerbeeck J; ;
J Clin Oncol; 2006 Mar; 24(9):1435-42. PubMed ID: 16446322
[TBL] [Abstract][Full Text] [Related]
27. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
Reck M; Heigener DF; Gatzemeier U
Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study.
Knuuttila A; Ollikainen T; Halme M; Mali P; Kivisaari L; Linnainmaa K; Jekunen A; Mattson K
Anticancer Drugs; 2000 Apr; 11(4):257-61. PubMed ID: 10898540
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors in mesothelioma.
Steele JP; Klabatsa A; Fennell DA; Palläska A; Sheaff MT; Evans MT; Shamash J; Rudd RM
Lung Cancer; 2005 Jul; 49 Suppl 1():S49-52. PubMed ID: 15894403
[TBL] [Abstract][Full Text] [Related]
30. [First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].
Burgin M; Gairard-Dory A-; Mennecier B; Molard A; Beretz L; Quoix A-
Rev Pneumol Clin; 2009 Apr; 65(2):75-83. PubMed ID: 19375046
[TBL] [Abstract][Full Text] [Related]
31. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.
Laurie SA; Gupta A; Chu Q; Lee CW; Morzycki W; Feld R; Foo AH; Seely J; Goffin JR; Laberge F; Murray N; Rao S; Nicholas G; Laskin J; Reiman T; Sauciuc D; Seymour L
J Thorac Oncol; 2011 Nov; 6(11):1950-4. PubMed ID: 22005473
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
[TBL] [Abstract][Full Text] [Related]
33. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials.
Francart J; Vaes E; Henrard S; Legrand C; Baas P; Gaafar R; van Meerbeeck JP; Sylvester R; Robert A
Eur J Cancer; 2009 Sep; 45(13):2304-11. PubMed ID: 19502050
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice.
Cordony A; Le Reun C; Smala A; Symanowski JT; Watkins J
Value Health; 2008; 11(1):4-12. PubMed ID: 18237355
[TBL] [Abstract][Full Text] [Related]
35. MVP and vinorelbine for malignant pleural mesothelioma.
Mordant P; Loriot Y; Soria JC; Deutsch E
Lancet; 2008 Aug; 372(9639):629; author reply 629-30. PubMed ID: 18722865
[No Abstract] [Full Text] [Related]
36. Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma?
Zahid I; Sharif S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):812-7. PubMed ID: 21345818
[TBL] [Abstract][Full Text] [Related]
37. [Clinico-pathological prognostic factors in malignant pleural mesothelioma].
Nakano K; Shiota Y; Ono T; Taniyama K; Hiramoto T; Yamakido M
Nihon Kokyuki Gakkai Zasshi; 2007 Feb; 45(2):153-9. PubMed ID: 17352172
[TBL] [Abstract][Full Text] [Related]
38. Systemic drug therapy of malignant pleural mesothelioma.
Ardizzoni A; Grossi F; Pennucci MC
Monaldi Arch Chest Dis; 1998 Apr; 53(2):236-40. PubMed ID: 9689814
[TBL] [Abstract][Full Text] [Related]
39. High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
Zimling ZG; Santoni-Rugiu E; Bech C; Sørensen JB
Anticancer Res; 2015 Dec; 35(12):6731-8. PubMed ID: 26637889
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
Steele JP; Shamash J; Evans MT; Gower NH; Tischkowitz MD; Rudd RM
J Clin Oncol; 2000 Dec; 18(23):3912-7. PubMed ID: 11099320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
